Bio Plus Co

Bio Plus Co Equity Ratio

The Equity Ratio of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 61.34 %. In the previous year, Equity Ratio was 50.51 % — a change of 21.45% (higher).

Equity Ratio

61.34 %

YoY

21.45%

Last updated:

Equity Ratio of Bio Plus Co is 2025 61.34 % . Equity Ratio of Bio Plus Co was 2024 50.51 % . It decreases by 21.45% higher compared to the previous year.

The Bio Plus Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
55.49 KRW
Jan 1, 2019
84.99 KRW
Jan 1, 2020
75.18 KRW
Jan 1, 2021
88.96 KRW
Jan 1, 2022
77.30 KRW
Jan 1, 2023
73.97 KRW
Jan 1, 2024
50.51 KRW
Jan 1, 2025
61.34 KRW
The Bio Plus Co Equity Ratio history
YEAREquity RatioYoY
61.34 %+21.45%
50.51 %-31.72%
73.97 %-4.32%
77.30 %-13.11%
88.96 %+18.33%
75.18 %-11.55%
84.99 %+53.16%
55.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Equity Ratio of Bio Plus Co is 61.34 % in 2025.

Equity Ratio of Bio Plus Co changed from 50.51 % to 61.34 %, representing a 21.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio Plus Co

All Key Metrics — Bio Plus Co